We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

67 hedge funds and large institutions have $37.2M invested in Cartesian Therapeutics in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

16% more call options, than puts

Call options by funds: $309K | Put options by funds: $266K

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 68 → 67 (-1)

3.2% less ownership

Funds ownership: 23.05% → 19.85% (-3.2%)

39% less capital invested

Capital invested by funds: $60.9M → $37.2M (-$23.7M)

Holders
67
Holders Change
-1
Holders Change %
-1.47%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
22
Reduced
17
Closed
16
Calls
$309K
Puts
$266K
Net Calls
+$43K
Net Calls Change
-$652K

Top Buyers

Rank Fund Capital Flow
1
PFM
Privium Fund Management
Netherlands
+$1.39M
2
Millennium Management
Millennium Management
New York
+$1.12M
3
Bank of America
Bank of America
North Carolina
+$801K
4
Marshall Wace
Marshall Wace
United Kingdom
+$755K
5
Two Sigma Investments
Two Sigma Investments
New York
+$738K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.38M
2
SL
Siren LLC
Connecticut
-$5.76M
3
MB
MPM BioImpact
Massachusetts
-$3.88M
4
BlackRock
BlackRock
New York
-$321K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$286K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$9.86M -$6.38M -788,794 -37%
BlackRock
2
BlackRock
New York
$4.4M -$321K -39,645 -6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.9M +$166K +20,506 +4%
6CM
4
683 Capital Management
New York
$2.02M +$404K +50,000 +22%
EAM
5
Erste Asset Management
Austria
$1.96M +$94.6K +11,694 +4%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.84M +$111K +13,710 +6%
State Street
7
State Street
Massachusetts
$1.43M +$10.5K +1,301 +0.7%
Marshall Wace
8
Marshall Wace
United Kingdom
$1.28M +$755K +93,334 +110%
PFM
9
Privium Fund Management
Netherlands
$1.24M +$1.39M +172,500 New
Millennium Management
10
Millennium Management
New York
$1.19M +$1.12M +139,009 +548%
Bank of America
11
Bank of America
North Carolina
$815K +$801K +99,023 +704%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$691K +$532K +65,798 +219%
Two Sigma Investments
13
Two Sigma Investments
New York
$658K +$738K +91,278 New
Northern Trust
14
Northern Trust
Illinois
$627K -$34.6K -4,276 -5%
Citadel Advisors
15
Citadel Advisors
Florida
$575K +$74.9K +9,261 +13%
GCP
16
GSA Capital Partners
United Kingdom
$557K -$71.7K -8,868 -10%
UBS Group
17
UBS Group
Switzerland
$486K +$464K +57,393 +577%
Walleye Capital
18
Walleye Capital
New York
$316K +$355K +43,878 New
Renaissance Technologies
19
Renaissance Technologies
New York
$296K +$332K +41,100 New
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$244K +$274K +33,871 New
Charles Schwab
21
Charles Schwab
California
$182K +$3.27K +405 +2%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$182K +$8.49K +1,050 +4%
BCM
23
Bridgeway Capital Management
Texas
$180K – – –
Two Sigma Advisers
24
Two Sigma Advisers
New York
$179K +$201K +24,808 New
N
25
Nuveen
North Carolina
$177K – – –
1
2 3 4

RNAC Hedge Fund Activity: Q4 2025 in Review

67 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2025, worth a combined $37.2M — down 39% from $60.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RNAC and 15 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 22 added.

The largest buyer was Privium Fund Management, opening a new position worth an estimated $1.39M. The largest seller was Fidelity Investments, cutting an estimated $6.38M.

  • 67 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2025, down from 68 in Q3 2025.
  • Funds reported $37.2M of Cartesian Therapeutics stock for Q4 2025, down 39% quarter-over-quarter.
  • 15 funds opened new Cartesian Therapeutics positions in Q4 2025 and 16 closed out, a net change of -1 holder.
  • The largest Cartesian Therapeutics buyer in Q4 2025 was Privium Fund Management, an estimated $1.39M added.
  • The largest Cartesian Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $6.38M sold.

Based on aggregated 13F filings for Q4 2025.